128 related articles for article (PubMed ID: 25551558)
21. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
22. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
[TBL] [Abstract][Full Text] [Related]
24. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
25. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
[TBL] [Abstract][Full Text] [Related]
26. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure.
Holguín A; Suñe C; Hamy F; Soriano V; Klimkait T
J Clin Virol; 2006 Aug; 36(4):264-71. PubMed ID: 16765636
[TBL] [Abstract][Full Text] [Related]
27. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
[TBL] [Abstract][Full Text] [Related]
28. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
Gianotti N; Tambussi G; Boeri E; Lazzarin A
J Biol Regul Homeost Agents; 2001; 15(2):166-9. PubMed ID: 11501975
[TBL] [Abstract][Full Text] [Related]
29. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.
Gonzalez LM; Brindeiro RM; Aguiar RS; Pereira HS; Abreu CM; Soares MA; Tanuri A
Antimicrob Agents Chemother; 2004 Sep; 48(9):3552-5. PubMed ID: 15328124
[TBL] [Abstract][Full Text] [Related]
30. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
31. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
Stoffler D; Sanner MF; Morris GM; Olson AJ; Goodsell DS
Proteins; 2002 Jul; 48(1):63-74. PubMed ID: 12012338
[TBL] [Abstract][Full Text] [Related]
32. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
[TBL] [Abstract][Full Text] [Related]
33. Robustness-epistasis link shapes the fitness landscape of a randomly drifting protein.
Bershtein S; Segal M; Bekerman R; Tokuriki N; Tawfik DS
Nature; 2006 Dec; 444(7121):929-32. PubMed ID: 17122770
[TBL] [Abstract][Full Text] [Related]
34. Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1.
Martínez JP; Bocharov G; Ignatovich A; Reiter J; Dittmar MT; Wain-Hobson S; Meyerhans A
PLoS One; 2011 Mar; 6(3):e18375. PubMed ID: 21483787
[TBL] [Abstract][Full Text] [Related]
35. Recombination and the evolution of mutational robustness.
Gardner A; Kalinka AT
J Theor Biol; 2006 Aug; 241(4):707-15. PubMed ID: 16487979
[TBL] [Abstract][Full Text] [Related]
36. A side chain at position 48 of the human immunodeficiency virus type-1 protease flap provides an additional specificity determinant.
Moody MD; Pettit SC; Shao W; Everitt L; Loeb DD; Hutchison CA; Swanstrom R
Virology; 1995 Mar; 207(2):475-85. PubMed ID: 7886951
[TBL] [Abstract][Full Text] [Related]
37. Epistatic interactions attenuate mutations affecting startle behaviour in Drosophila melanogaster.
Yamamoto A; Anholt RR; MacKay TF
Genet Res (Camb); 2009 Dec; 91(6):373-82. PubMed ID: 19968911
[TBL] [Abstract][Full Text] [Related]
38. Constrained Mutational Sampling of Amino Acids in HIV-1 Protease Evolution.
Boucher JI; Whitfield TW; Dauphin A; Nachum G; Hollins C; Zeldovich KB; Swanstrom R; Schiffer CA; Luban J; Bolon DNA
Mol Biol Evol; 2019 Apr; 36(4):798-810. PubMed ID: 30721995
[TBL] [Abstract][Full Text] [Related]
39. Moderate Amounts of Epistasis are Not Evolutionarily Stable in Small Populations.
Sydykova DK; LaBar T; Adami C; Wilke CO
J Mol Evol; 2020 Jul; 88(5):435-444. PubMed ID: 32350572
[TBL] [Abstract][Full Text] [Related]
40. Selection for chaperone-like mediated genetic robustness at low mutation rate: impact of drift, epistasis and complexity.
Gros PA; Tenaillon O
Genetics; 2009 Jun; 182(2):555-64. PubMed ID: 19307609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
